Vivoryon Therapeutics NV
Research Vivoryon Therapeutics NV (VVY) on Bullrun: market cap EUR 33.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVVY
- ExchangeAS
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 33.61M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 8.85M
- Free cash flow-EUR 8.46M
Valuation Snapshot
latest market cap is EUR 33.61M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 8.85M | -EUR 8.46M | n/a | n/a | EUR 5.62M | EUR 108.00K | EUR 4.73M |
| FY2024 | EUR 0 | -EUR 20.57M | -EUR 19.18M | n/a | -0.79 | EUR 9.37M | EUR 102.00K | EUR 7.88M |
| FY2023 | -EUR 3.62M | -EUR 28.34M | -EUR 22.06M | 85.5% | -1.12 | EUR 18.56M | EUR 38.00K | EUR 26.28M |
| FY2022 | EUR 0 | -EUR 28.16M | -EUR 21.81M | n/a | -1.28 | EUR 26.56M | EUR 132.00K | EUR 26.51M |
| FY2021 | n/a | n/a | n/a | n/a | -0.63 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | EUR 33.61M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
Company Brief
Vivoryon Therapeutics develops therapies targeting glutaminyl cyclases to treat diabetic kidney disease, supported by growing evidence validating these targets.
The company is scheduled to report its full year 2025 financial results and business updates on April 23, 2026, while presenting at an upcoming investor conference.
Despite a net income increase of 57% year-over-year compared to the prior period, Vivoryon remains loss-making as reported for FY2025.
Investors should monitor the company's full year 2025 financial results and business updates when released on April 23, 2026.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vivoryon Therapeutics NV's market cap?
Vivoryon Therapeutics NV's market capitalization is EUR 33.61M.
What does Vivoryon Therapeutics NV do?
Vivoryon Therapeutics develops therapies targeting glutaminyl cyclases to treat diabetic kidney disease, supported by growing evidence validating these targets.